MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$14,064K
Free Cash flow
-$46,882K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from sales and maturiti...
Stock-based compensation expense
Accrued expenses and other curre...
Others
Negative Cash Flow Breakdown
Purchases of investments
Net loss
Other assets
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-79,056
-60,202
-41,309
-43,808
Depreciation and amortization
850
841
849
416
Stock-based compensation expense
14,334
6,474
7,187
7,331
Accretion of discount on short-term investments
-
-
-951
-201
Unrealized losses (gains) on short-term investments
-3,004
-1,664
-
-
Non-cash interest expense (income)
-46
-46
-76
844
Non-cash lease expense
25
13
13
8
Prepaid expenses and other current assets
-3,184
8,066
1,810
105
Accounts receivable, net
-858
587
301
19
Inventory
-490
-72
64
380
Other assets
2,053
998
1,564
7
Accounts payable
4,491
2,522
-3,479
1,227
Accrued expenses and other current liabilities
7,738
1,607
3,731
-3,379
Other liabilities
-325
-329
-496
9
Net cash used in operating activities
-46,414
-56,943
-36,216
-38,894
Proceeds from sales and maturities of investments
226,902
252,853
222,240
621,899
Purchases of investments
196,006
587,394
297,738
770,122
Acquisition, net of cash acquired
-
-
0
21,967
Purchases of property and equipment
468
304
7
97
Net cash used in investing activities
30,428
-334,845
-75,505
15,045
Proceeds from follow-on public offerings, net of issuance costs
0
391,550
98,449
49,001
Proceeds from exercise of common stock options
2,081
1,669
656
5,099
Withholding taxes paid on net exercise of stock options
20
174
-
-
Deferred offering costs
-
-
-
270
Stock issuance costs
139
47
316
-
Net cash provided by financing activities
1,922
392,998
99,066
54,370
Net decrease in cash and cash equivalents
-14,064
1,210
-12,655
30,521
Cash and cash equivalents at beginning of period
33,700
32,490
45,145
257,068
Cash and cash equivalents at end of period
19,636
33,700
32,490
45,145
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sales and
maturities of investments
$226,902K
Proceeds from exercise of
common stock options
$2,081K
(196.86%↑ Y/Y)
Net cash used in
investing activities
$30,428K
(116.42%↑ Y/Y)
Net cash provided by
financing activities
$1,922K
(1148.05%↑ Y/Y)
Canceled cashflow
$196,474K
Canceled cashflow
$159K
Net decrease in cash
and cash...
-$14,064K
(94.20%↑ Y/Y)
Canceled cashflow
$32,350K
Stock-based compensation
expense
$14,334K
(17.90%↑ Y/Y)
Accrued expenses and
other current...
$7,738K
(-6.80%↓ Y/Y)
Accounts payable
$4,491K
(638.65%↑ Y/Y)
Prepaid expenses and
other current assets
-$3,184K
(-21126.67%↓ Y/Y)
Unrealized losses (gains)
on short-term...
-$3,004K
Accounts receivable, net
-$858K
Depreciation and
amortization
$850K
(372.22%↑ Y/Y)
Inventory
-$490K
Non-cash interest
expense (income)
-$46K
Non-cash lease expense
$25K
(92.31%↑ Y/Y)
Purchases of investments
$196,006K
Purchases of property and
equipment
$468K
(1460.00%↑ Y/Y)
Stock issuance costs
$139K
Withholding taxes paid on net
exercise of stock options
$20K
Net cash used in
operating activities
-$46,414K
(18.91%↑ Y/Y)
Canceled cashflow
$35,020K
Net loss
-$79,056K
(-4.19%↓ Y/Y)
Other assets
$2,053K
(15692.31%↑ Y/Y)
Other liabilities
-$325K
Buy us a coffee
CG Oncology, Inc. (CGON)
CG Oncology, Inc. (CGON)